Literature DB >> 14609743

In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine.

Romina Gamberale1, Carlos M Galmarini, Paula Fernández-Calotti, Lars Jordheim, Julio Sánchez-Avalos, Charles Dumontet, Jorge Geffner, Mirta Giordano.   

Abstract

Administration of the adenosine analogue fludarabine (FLU) in vivo induces a profound and prolonged T lymphopenia which mainly affects CD4(+) cells. To better understand the mechanistic basis underlying this preferential depletion, we analyzed the in vitro susceptibility of T cell subsets to FLU-induced apoptosis. Contrasting with observations in vivo, our results showed that treatment of peripheral blood mononuclear cells with FLU induced a higher level of apoptosis in CD8(+) than in CD4(+) T lymphocytes. This increased sensitivity of CD8(+) T cells to FLU was observed in samples from both, healthy donors and B cell chronic lymphocytic leukemia patients, and resulted in higher CD4:CD8 ratios in FLU-treated than in untreated cultures (P<0.01). Expression of factors involved in FLU transport and metabolism was then evaluated by quantitative real time-PCR in normal T cell subsets. It was found that mRNA levels of human equilibrative nucleoside transporter-1 nucleoside transporter were higher whereas deoxycytidine kinase and IMP/GMP selective 5'-nucleotidase mRNA levels were lower in CD4(+) cells. However the dCK/cN-II ratio was 2-fold greater in CD8(+) than in CD4(+) T lymphocytes, which could account for the higher apoptosis levels observed in the CD8(+) subset. These results favor the view that decreased CD4:CD8 ratios in FLU-treated patients should be attributed to differences in cell recovery and/or homing between T cell subsets.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14609743     DOI: 10.1016/j.bcp.2003.07.008

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

1.  Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.

Authors:  Hayato Fujita; Kenoki Ohuchida; Kazuhiro Mizumoto; Soichi Itaba; Tetsuhide Ito; Kohei Nakata; Jun Yu; Tadashi Kayashima; Ryota Souzaki; Tatsuro Tajiri; Tatsuya Manabe; Takao Ohtsuka; Masao Tanaka
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Autoimmune thrombocytopenia: a complication of fludarabine therapy in the treatment of Waldenstrom's macroglobulinemia.

Authors:  Yujie Jiang; Hongjuan Peng; Xin Cui; Ying Zhou; Dai Yuan; Xiaohui Sui; Lingyan Zhang; Hongzhi Xu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  COVID-19 and Cancer Patients.

Authors:  Rajvi Patel; Jennifer Park; Ankit Shah; Muhammad Wasif Saif
Journal:  Cancer Med J       Date:  2020-04-03

4.  A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.

Authors:  Meagan J Bemer; Mohamed Sorror; Brenda M Sandmaier; Paul V O'Donnell; Jeannine S McCune
Journal:  Cancer Chemother Pharmacol       Date:  2013-08-02       Impact factor: 3.333

5.  Cyclophosphamide and fludarabine monophosphate dose optimization for the non-myeloablative condition in non-human primates to induce transient mixed chimerism via bone marrow transplantation.

Authors:  Yeongbeen Kwon; Kyo Won Lee; Hyojun Park; Jin Kyung Son; JongHyun Lee; Chan Woo Cho; Ghee Young Kwon; Jae Berm Park; Sung Joo Kim
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

6.  Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

Authors:  Jeannine S McCune; Paolo Vicini; David H Salinger; Paul V O'Donnell; Brenda M Sandmaier; Claudio Anasetti; Donald E Mager
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-06       Impact factor: 3.333

7.  Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.

Authors:  Jeannine S McCune; Donald E Mager; Meagan J Bemer; Brenda M Sandmaier; Barry E Storer; Shelly Heimfeld
Journal:  Cancer Chemother Pharmacol       Date:  2015-05-17       Impact factor: 3.333

8.  Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts.

Authors:  Christian H Poehlein; Daniel P Haley; Edwin B Walker; Bernard A Fox
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

9.  Intracellular disposition of fludarabine triphosphate in human natural killer cells.

Authors:  Erica L Woodahl; Joanne Wang; Shelly Heimfeld; Brenda M Sandmaier; Jeannine S McCune
Journal:  Cancer Chemother Pharmacol       Date:  2008-09-10       Impact factor: 3.333

10.  Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma.

Authors:  Franck Laporte; Safouane Hamdi; Françoise Oksman; Françoise Huguet
Journal:  Pharm World Sci       Date:  2008-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.